Parvathy Chandra K, Deepti Ramakrishnan, Joy Augustine


 Ki67 is a proliferative marker which has therapeutic, predictive and prognostic value in breast carcinoma. The aim of the study was to analyse the correlation of Ki-67 labeling index with other prognostic markers like ER, PR, and HER2.

 This was a hospital based cross sectional comparative analysis conducted in Department of Pathology, Amala institute of Medical Sciences, Kerala, India during a period of 18 months, from January 2015 to June 2016. In total, 230 specimens of lumpectomy, mastectomy and trucut biopsies from primary breast cancer patients were enrolled in the study.

 The immunohistochemical staining for Ki 67,Estrogen Receptor(ER), Progesterone Receptor(PR), and Human Epidermal growth factor Receptor 2(HER2) were done and scored according to specific criteria. The association between Ki 67 scores and others were evaluated.


Ki67; ER; HER2; correlation

Full Text:



Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre M et al. The Global Burden of Cancer 2013. JAMA Oncology. 2015;1(4):505

Han G. ER, PR and HER2 testing in breast cancer. Diagnostic Histopathology. 2014;20(11):440-445

Min KW, Kim DH, Do SI, Pyo JS, Chae SW, Sohn JH, Kim K, Lee HJ, Kim DH, Oh S, Choi SH. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer. Postgraduate medical journal. 2016 May 24:postgradmedj-2015.

Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn H-J, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol. 2009 Aug 1;20(8):1319–29.

Singhai R, Patil V, Patil A. Status of HER-2/neu receptors and Ki-67 in breast cancer of Indian women. Int J Appl Basic Med Res. 2011;1(1):15.

Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, et al. Male Breast Carcinoma: Correlation of ER, PR, Ki-67, Her2-Neu, and p53 with Treatment and Survival, a Study of 65 Cases. Mod Pathol. 2002 Aug;15(8):853–61.

Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer. J Clin Oncol. 2010 Jan 10;28(2):232–9

Siadati S, Sharbatdaran M, Nikbakhsh N, Ghaemian N. Correlation of ER, PR and HER-2/Neu with other Prognostic Factors in Infiltrating Ductal Carcinoma of Breast. Iranian Journal of Pathology. 2015;10(3):221-226.

Thang VH, Skoog L, Duc NB, Van TT, Tani E. Cell Proliferation Measured by Ki67 Staining and Correlation to Clinicopathological Parameters in Operable Breast Carcinomas from Vietnamese and Swedish Patients. J Anal Oncol. 2015;4(2):58–68.

Singhai R, Patil V, Patil A. Status of HER-2/neu receptors and Ki-67 in breast cancer of Indian women. Int J Appl Basic Med Res. 2011;1(1):15.

Sun J, Chen C, Wei W, Zheng H, Yuan J, Tu Y, Yao F, Wang L, Yao X, Li J, Li Y. Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study. Oncology letters. 2015 Sep 1;10(3):1741-8.

Haroon S, Hashmi AA, Khurshid A, Kanpurwala MA, Mujtuba S, Malik B, et al. Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients. Asian Pac J Cancer Prev. 2013;14(7):4353–4358.


  • There are currently no refbacks.